In 2023, Carole Ben-Maimon, M.D. earned $865.00K in total compensation at Larimar Therapeutics, including $560.00K salary and $288.40K bonus. 5+ years at the helm of Larimar Therapeutics.
Compensation History
Annual executive compensation data for Carole Ben-Maimon, M.D., including salary, bonuses, and stock awards.
Year
2023
Total Compensation
$865.00K
Salary
$560.00K
Bonus
$288.40K
Other
$16.60K
Salary
$560.00KBoard Justification
Our executive compensation program is designed to attract, motivate and retain our named executive officers who are critical to our success, aligning with our pay-for-performance philosophy.
Bonus
$288.40KBoard Justification
Represents bonus paid in February 2024 based upon 2023 corporate performance, as approved by our Compensation Committee or Board, as applicable.
Other Compensation
$16.60KBoard Justification
Includes the Company’s contribution to a 401(k) plan and the value of group term life benefits provided by the Company.
Restricted Stock
Board Justification
No stock was reported as vested in 2023.
Performance Metrics
The 2023 annual bonuses for Dr. Ben-Maimon were targeted at 50% of her base salary, with an overall achievement level of 103%.
Carole Ben-Maimon, M.D.
CEO of Larimar Therapeutics
Education
B.S. from the University of Pennsylvania; M.D. from Jefferson Medical College.
Sector of Economy
Healthcare
Born
January 1, 1961 - 64 years ago
CEO of Larimar Therapeutics for
5 years 6 months (May 2020 - Present)
Previous Experience
President and CEO of Chondrial Therapeutics, Inc.; President of Global Pharmaceuticals at Impax Laboratories; various roles in Barr Pharmaceuticals and Teva Pharmaceutical Industries.
Other Larimar Therapeutics CEOs
Holdings
Track Carole Ben-Maimon, M.D.'s stock holdings and portfolio value over time.
Insider Trading
Carole Ben-Maimon, M.D.'s recent stock transactions, purchases, and sales filed with the SEC.
No insider trades found for this CEO.
Rivals
Compare Carole Ben-Maimon, M.D. with competitor CEOs and industry peers.